ARBE vs HIT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ARBE exhibits severe financial distress despite strong revenue growth, as reflected in its Piotroski F-Score of 1/9 (indicating poor financial health) and the absence of an Altman Z-Score (raising bankruptcy risk concerns). The company reports massive losses, negative margins across all metrics, and a negative ROE of -142.69%, signaling deep operational inefficiency. While revenue growth is impressive at 362.6% YoY, this is not translating into profitability or cash flow. The stock trades at an extreme Price/Sales of 90.41, far above peers and historical norms, suggesting significant overvaluation. Analysts rate it 'strong_buy' with a target of $2.25, but this is not supported by fundamentals.
HIT presents a high-risk profile characterized by a Piotroski F-Score of 4/9 (Stable) but severe technical deterioration. While the company exhibits strong revenue growth (53.10%) and an exceptionally clean balance sheet (Debt/Equity 0.01), it is trading at a massive premium to its Graham Number ($0.37) and Intrinsic Value ($0.14). The stock is currently in a freefall with a 0/100 technical trend and a 60.8% decline over the last six months, coupled with a poor earnings track record of 0/4 beats.
Compare Another Pair
Related Comparisons
ARBE vs HIT: Head-to-Head Comparison
This page compares Arbe Robotics Ltd. (ARBE) and Health In Tech, Inc. (HIT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.